News and Comments

Elan's Choices

  Saturday, April 16, 2011

Biogen Idec (BIIB) announced positive results of a process aimed at Identifying high-risk patients for a life-threatening side effect of prolonged use of the multiple sclerosis drug Tysabri. This test is a necessity because it detects an antibody that points to the presence of the Polyomavirus JC (JC virus), which causes the life-threatening progressive multifocal leukoencephalopathy (PML). This side effect in one per thousand patients has deprived Elan from billions of dollars in expected sales of Tysabri.  More...


Recent Postings


Archive


Tags

Roche (ROCHE) Exelixis (EXEL) Sanofi (SNY) CompuGen (CGEN) Alnylam (ALNY) Gilead (GILD) Valeant Pharmaceuticals International (VRX) Ziofpharm (ZIOP) Inovio (INO) Sanofi (SNA) Prolor Biotech (PBTH) TOKAI (TKAOI) Bristol-Myers Squibb (BMY) Jazz Pharmaceuticals (JAZZ) Illumina (ILMN) Theravance (THRX) Zerenex Velcade (bortezomib) Ridaforolimus Pluristem (PSTI) Prosensa (RNA) Vertex (VRTX) Onyx (ONXX) Telaprevir Array Pharmaceuticals (ARRY) Sanofi-Aventis (SAN) ISIS (ISIS) Agenus (AGEN KERYX (KERX) ImmunoGen (IMGN) GUARDIAN HEALTH Sarepta (SRPT) Anadys (ANDS) Mirati Therapeutics (MRTX) Human Genome Sciences (HGSI) Elan (ELN) Revlimid (lenolidamide) Multiple Myeloma ZALTRAP™ IDERA (IDRA) Galena (GALE) Aimmune Therapeutics (AIMT) Sequenom (SQNM) NANTKWEST (NK) ARCA (ABIO) AERIE PHARMACEUTICALS Agenus (AGEN) Incyte (INCY) BIOMARIN (BMRN) Seattle Genetics (SGEN) SERES THERAPEUTICS (MCRB) VANDA (VNDA) Xoma (XOMA) ABBVIE (ABBV) HALOZYME (HALO) Anacor (ANAC) KITE (KITE) Intrexon (XON) Sangamo (SGMO) Rapamune C4 Therapeutics GlaxoSmithKline (GSK) Dendreon (DNDN) galapagos (GLPG) Auspex (ASPX) Regeneron (REGN) SYNTA (SNTA) Genentech Amgen (AMGN) Cytokinetics (CYTK) Endometrial Cancer Idenix (IDIX) SUNESIS PHARMACEUTICALS (SNSS) Abbott Laboratories (ABT) Biogen Idec (BIIB) JUNO (JUNO) Dynavax (DVAX) Roche (RHHBY) Biocryst (BCRX) Micromet (MITI) Ariad (ARIA) ADVENTRIX (ANX) Herceptin NEKTAR (NKTR)) Intermune (ITMN) Trastuzumab-DM1 Tysabri Intercept (ICPT) Merck (MRK) OSI (OSIP) Benlysta (belimumab)